Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Refractory soft tissue sarcoma remains a difficult malignancy to treat. The mammalian target
of rapamycin (mTOR) is an enzyme that plays an important role in cancer cell survival. mTOR
inhibitors, like temsirolimus, have shown activity in sarcoma. Irinotecan is a chemotherapy
drug that has also been used to treat sarcoma. However, it is unknown whether combining these
two drugs would result in improved efficacy with acceptable toxicity.
Therefore, the goal of this phase I study is to determine the maximum tolerated dose (MTD)
and toxicity profile of combination temsirolimus and irinotecan both administered
intravenously on a weekly basis to refractory soft tissue sarcoma patients.
Phase:
Phase 1
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Camptothecin Complement Factor H Everolimus Irinotecan Sirolimus